



Edgar Filing: Calithera Biosciences, Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Series A Preferred Stock	Â (1)	Â (1)	Common Stock	6,808	\$ (1)	I	Delphi Ventures VIII, L.P. (2)
Series A Preferred Stock	Â (1)	Â (1)	Common Stock	66	\$ (1)	I	Delphi BioInvestments VIII, L.P. (3)
Series B Preferred Stock	Â (1)	Â (1)	Common Stock	415,128	\$ (1)	I	Delphi Ventures VIII, L.P. (2)
Series B Preferred Stock	Â (1)	Â (1)	Common Stock	4,053	\$ (1)	I	Delphi BioInvestments VIII, L.P. (3)
Series C Preferred Stock	Â (1)	Â (1)	Common Stock	740,312	\$ (1)	I	Delphi Ventures VIII, L.P. (2)
Series C Preferred Stock	Â (1)	Â (1)	Common Stock	7,228	\$ (1)	I	Delphi BioInvestments VIII, L.P. (3)
Series D Preferred Stock	Â (1)	Â (1)	Common Stock	745,825	\$ (1)	I	Delphi Ventures VIII, L.P. (2)
Series D Preferred Stock	Â (1)	Â (1)	Common Stock	7,282	\$ (1)	I	Delphi BioInvestments VIII, L.P. (3)

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Delphi Management Partners VIII, L.L.C. C/O DELPHI VENTURES, 3000 SAND HILL ROAD, BLDG. 1, SUITE 135 MENLO PARK, CA 94025	Â	Â X	Â	Â
DELPHI VENTURES VIII LP 3000 SAND HILL RD. BLDG 1, SUITE 135 MENLO PARK, CA 94025	Â	Â X	Â	Â
Delphi BioInvestments VIII LP 3000 SAND HILL RD. BLDG 1, SUITE 135 MENLO PARK, CA 94025	Â	Â X	Â	Â
ROEDER DOUGLAS A C/O DELPHI VENTURES	Â	Â X	Â	Â

3000 SAND HILL RD., BLDG 1, SUITE 135  
 MENLO PARK, CA 94025

DOUGLASS DAVID L  
 C/O DELPHI VENTURES  
 3000 SAND HILL RD., BLDG 1, SUITE 135     ^     ^ X     ^     ^  
 MENLO PARK, CA 94025

BOCHNOWSKI JAMES J  
 C/O DELPHI VENTURES  
 3000 SAND HILL RD., BLDG 1, SUITE 135     ^     ^ X     ^     ^  
 MENLO PARK, CA 94025

PAKIANATHAN DEEPIKA  
 C/O DELPHI VENTURES  
 3000 SAND HILL ROAD, BLDG. 1, SUITE 135     ^ X     ^ X     ^     ^  
 MENLO PARK, CA 94025

## Signatures

By: /s/ Matthew T. Potter, Name: Matthew T. Potter, Attorney-in-Fact for: Delphi Management Partners VIII, L.L.C., Delphi Ventures VIII, L.P., Delphi BioInvestments VIII, L.P., Deepika R. Pakianathan, Douglas A. Roder, David L. Douglass and James J. Bochnowski     10/01/2014

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The preferred stock is convertible at any time, at the holder's election, and has no expiration date. The preferred stock will automatically convert into common stock on a 1-to-1 basis upon closing of the initial public offering of the issuer.
- The reported securities are directly owned by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII") is the general partner of DV VIII and may be deemed to have sole voting and dispositive power over the securities held by DV VIII.
- (2) VIII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DV VIII. Such persons and entities disclaim beneficial ownership of the securities held by DV VIII, except to the extent of any pecuniary interest therein.
- The reported securities are directly owned by Delphi BioInvestments VIII, L.P. ("DBI VIII"). DMP VIII is the general partner of DBI VIII and may be deemed to have sole voting and dispositive power over the securities held by DBI VIII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DBI VIII. Such persons and entities disclaim beneficial ownership of the securities held by DBI VIII, except to the extent of any pecuniary interest therein.
- (3)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.